Regarding Cellceutix's drug for the treatment of psoriasis, KM-133, the Company has optimized the drug and has completed writing the patent application. Cellceutix's intellectual property law firm, Ladas & Parry, will now be filing of patents for KM-133. The Company will be interacting with the FDA regarding obtaining 505(b)(2) designation for KM-133 so it may be advanced immediately to Phase II clinical trials. Investors are encouraged to see the results of mouse model research in which KM-133 basically eliminated all signs of psoriasis as compared to controls at http://www.cellceutix.com/product-candidates/km-133---psoriasis-compound.html. KM-133 contains an active moiety which has already received FDA approval and, as such, the Company believes will make it eligible for advanced human trials from the onset.